Adjunctive therapy in patients with treatment failure or relapse of brucellosis

Efficacy of L- arginine in the treatment of brucellosis patients with treatment failure or relapse

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201407159855N7

Enrollment

Registered

2014-08-11

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malta fever. Brucellosis

Interventions

Intervention 1: Case group treated with doxycycline 200 mg daily plus rifampin 600 mg daily for 2 months with L - arginine 2 gram daily for 3 weeks. Intervention 2: Control group treated with doxycycl

Treatment - Drugs

Case group treated with doxycycline 200 mg daily plus rifampin 600 mg daily for 2 months with L - arginine 2 gram daily for 3 weeks

Control group treated with doxycycline 200 mg daily plus rifampin 600 mg daily for 2 months with placebo 2 gram daily for 3 weeks

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with clinical signs of brucellosis; history and treatment of brucellosis from 2 months ago; at least 6-8 week course of treatment for brucellosis; positive culture, positive PCR or serology with at least 1:160 of Wright and 1:80 2ME. Exclusion criteria included age less than 15 years; pregnant women; having an innate or acquired immunodeficiency; Allergy to arginine; Local forms of brucellosis infection; such as endocarditis, spondylitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treatment failure. Timepoint: Weeks of 2 , 4 , 6 , 8. Method of measurement: Questionnaire for reviewing of clinical signs and symptoms plus laboratory studies.;Relapse. Timepoint: Months of 3 , 5 , 7 , 9. Method of measurement: Questionnaire for reviewing of clinical signs and symptoms plus laboratory studies.	—

Secondary

Measure	Time frame
C-reactive protein reduction trend. Timepoint: Days 0 , 7 , 14 , 28 , 42 , 56. Method of measurement: The measurement of protein c.;Trend of reducing the Wright titer. Timepoint: Months of 1 , 3 , 5 , 7 , 9. Method of measurement: Measurement of the wright titer.;Trend of improving clinical symptoms and signs. Timepoint: Days 0 , 3 , 7 , 28 , 14 , 21 , 28. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Aliasghar Farazi

Arak University of Medical Sciences

farazialiasghar@yahoo.com+98 86 3224 1411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026